» Articles » PMID: 36142383

Potent Chlorambucil-Platinum(IV) Prodrugs

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Sep 23
PMID 36142383
Authors
Affiliations
Soon will be listed here.
Abstract

The DNA-alkylating derivative chlorambucil was coordinated in the axial position to atypical cytotoxic, heterocyclic, and non-DNA coordinating platinum(IV) complexes of type, (where H is 1,10-phenanthroline, 5-methyl-1,10-phenanthroline or 5,6-dimethyl-1,10-phenanthroline, A is 1,2-diaminocyclohexane). The resultant platinum(IV)-chlorambucil prodrugs, , , and , were characterized using high-performance liquid chromatography, nuclear magnetic resonance, ultraviolet-visible, circular dichroism spectroscopy, and electrospray ionization mass spectrometry. The prodrugs displayed remarkable antitumor potential across multiple human cancer cell lines compared to chlorambucil, cisplatin, oxaliplatin, and carboplatin, as well as their platinum(II) precursors, , , and . Notably, was exceptionally potent in HT29 colon, Du145 prostate, MCF10A breast, MIA pancreas, H460 lung, A2780, and ADDP ovarian cell lines, with GI values ranging between 2.7 and 21 nM. Moreover, significant production of reactive oxygen species was detected in HT29 cells after treatment with , , and up to 72 h compared to chlorambucil and the platinum(II) and (IV) precursors.

Citing Articles

Bifunctional Oxaliplatin (IV) Prodrug Based pH-Sensitive PEGylated Liposomes for Synergistic Anticancer Action Against Triple Negative Breast cancer.

Bhute L, Dighe S, Katari O, Yadav V, Jain S AAPS PharmSciTech. 2024; 26(1):2.

PMID: 39633214 DOI: 10.1208/s12249-024-02988-3.


Chemotherapeutic Potential of Chlorambucil-Platinum(IV) Prodrugs against Cisplatin-Resistant Colorectal Cancer Cells.

Elias M, Aputen A, Fatima S, Mann T, Karan S, Mikhael M Int J Mol Sci. 2024; 25(15).

PMID: 39125821 PMC: 11312340. DOI: 10.3390/ijms25158252.


Anticancer Effect of PtPHEN, Pt5ME, Pt56ME and Their Platinum(IV)-Dihydroxy Derivatives against Triple-Negative Breast Cancer and Cisplatin-Resistant Colorectal Cancer.

Elias M, Fatima S, Mann T, Karan S, Mikhael M, de Souza P Cancers (Basel). 2024; 16(14).

PMID: 39061185 PMC: 11274883. DOI: 10.3390/cancers16142544.


Platinum(IV) Prodrugs Incorporating an Indole-Based Derivative, 5-Benzyloxyindole-3-Acetic Acid in the Axial Position Exhibit Prominent Anticancer Activity.

Aputen A, Elias M, Gilbert J, Sakoff J, Gordon C, Scott K Int J Mol Sci. 2024; 25(4).

PMID: 38396859 PMC: 10888562. DOI: 10.3390/ijms25042181.


Combination of Chlorambucil and Mercaptopurine Show Effective Anti-Cancer Effects in Mice Model.

Xu W, Di Y, Chu S, Wang Z, Long H, Pu L Int J Nanomedicine. 2024; 18:8131-8141.

PMID: 38169995 PMC: 10759911. DOI: 10.2147/IJN.S438742.


References
1.
Boulanger J, Boursiquot J, Cournoyer G, Lemieux J, Masse M, Almanric K . Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations. Curr Oncol. 2014; 21(4):e630-41. PMC: 4117628. DOI: 10.3747/co.21.1966. View

2.
Deo K, Sakoff J, Gilbert J, Zhang Y, Aldrich Wright J . Synthesis, characterisation and potent cytotoxicity of unconventional platinum(iv) complexes with modified lipophilicity. Dalton Trans. 2019; 48(46):17217-17227. DOI: 10.1039/c9dt03339d. View

3.
Krause-Heuer A, Grunert R, Kuhne S, Buczkowska M, Wheate N, Le Pevelen D . Studies of the mechanism of action of platinum(II) complexes with potent cytotoxicity in human cancer cells. J Med Chem. 2009; 52(17):5474-84. DOI: 10.1021/jm9007104. View

4.
Basu U, Banik B, Wen R, Pathak R, Dhar S . The Platin-X series: activation, targeting, and delivery. Dalton Trans. 2016; 45(33):12992-3004. PMC: 4987247. DOI: 10.1039/c6dt01738j. View

5.
Oun R, Moussa Y, Wheate N . The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans. 2018; 47(19):6645-6653. DOI: 10.1039/c8dt00838h. View